




The relative strengths and weaknesses of VYNE Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 149% points. The greatest weakness of VYNE Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 54% points.

The company's Economic Capital Ratio, given in the ranking table, is 309%, being 79% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	30,010
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,395
Liabilities, Non-Current	0
Other Assets	60
Other Compr. Net Income	-18
Other Expenses	4.0
Other Liabilities	0
Other Net Income	3,270
Other Revenues	570
Property and Equipment	90
Research and Development	19,237
Selling, General and Administrative Expense	11,082

Output Variable	Value in 1000 USD
Assets	30,160
Liabilities	2,395
Expenses	30,323
Revenues	570
Stockholders Equity	27,765
Net Income	-26,483
Comprehensive Net Income	-26,492
BaseVar	33,368
ECR before LimitedLiability	209%
Economic Capital Ratio	309%